anti-FcRL5 TCE

Anti-FcRL5 TCE refers to a class of bispecific T-cell engagers (TCEs) designed to treat multiple myeloma by targeting Fc receptor-like 5 (FcRL5), a surface protein highly expressed on malignant plasma cells. These agents are engineered with dual binding domains: one specific for FcRL5 on the tumor cell and another for the CD3 epsilon subunit of the T-cell receptor complex. By cross-linking these two cells, the TCE induces T-cell activation, secretion of cytotoxic granules (perforin and granzymes), and subsequent lysis of the myeloma cell, independent of MHC-I presentation. The most prominent clinical candidate in this class is cevostamab (BFCR4350A/RG6160), developed by Genentech and Roche, which has demonstrated clinical activity in patients with relapsed or refractory multiple myeloma, including those previously treated with BCMA-targeted therapies.

Other names

FcRL5-CD3 bispecific antibodyFcRL-5-CD3 bispecific antibodyFcRL 5-CD3 bispecific antibodyFcRL5 T-cell engagerFcRL-5 T-cell engagerFcRL 5 T-cell engageranti-FcRL5 bispecific antibodyanti-FcRL-5 bispecific antibodyanti-FcRL 5 bispecific antibody